The Role of P53 and MDM2 in Head and Neck Cancer

Overview

Journal ISRN Otolaryngol

Specialty Otorhinolaryngology

Date 2013 Jun 1

PMID 23724261

Citations 9

Authors

N Denaro

C Lo Nigro

G Natoli

E G Russi

V Adamo

M C Merlano

Affiliations

Soon will be listed here.

Abstract

Head and neck cancer is a complex disorder that includes mostly squamous cell carcinomas that can develop in the throat, larynx, nose, sinuses, and mouth. Etiopathogenesis is due to tobacco and alcohol consumption and to infection by human papillomavirus (HPV) type 16/18. Tumors often develop within preneoplastic fields of genetically altered cells. Most head and neck cancers result from multistep accumulation of genetic alterationsm resulting in clonal outgrowth of transformed cells. These DNA changes are caused by a variety of mechanisms like endogenous mutations and exogenous mutations. Dysregulated molecular pathway includes alterations of critical inhibitor of cyclin CDK complexes, inactivating mutations of p53 gene, and activation of oncogenes and growth factors. This paper attempts to review the role of p53 and MDM2 genetic aberrations and pathways in head and neck cancer.

Citing Articles

Identification of p53-target genes in human papillomavirus-associated head and neck cancer by integrative bioinformatics analysis.

Bouzid A, Al Ani M, de la Fuente D, Al Shareef Z, Quadri A, Hamoudi R Front Oncol. 2023; 13:1128753.

PMID: 37081989 PMC: 10110890. DOI: 10.3389/fonc.2023.1128753.

AGO-RBP crosstalk on target mRNAs: Implications in miRNA-guided gene silencing and cancer.

Kakumani P Transl Oncol. 2022; 21:101434.

PMID: 35477066 PMC: 9136600. DOI: 10.1016/j.tranon.2022.101434.

Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer.

Bos T, Ratti J, Harada H Front Oral Health. 2022; 2:676643.

PMID: 35048023 PMC: 8757684. DOI: 10.3389/froh.2021.676643.

Neural reprogramming via microRNAs: the new kid on the p53-deficient block.

Silverman D, Calin G, Myers J, Amit M Mol Cell Oncol. 2020; 7(4):1756723.

PMID: 32944617 PMC: 7469510. DOI: 10.1080/23723556.2020.1756723.

Combined Effect of HPV and Several Gene SNPs in Laryngeal Cancer.

Stumbryte-Kaminskiene A, Gudleviciene Z, Dabkeviciene D, Mackeviciene I Medicina (Kaunas). 2020; 56(2).

PMID: 32079256 PMC: 7074362. DOI: 10.3390/medicina56020081.

References

Farnebo L, Jedlinski A, Ansell A, Vainikka L, Thunell L, Grenman R . Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. Int J Mol Med. 2009; 24(4):549-56. DOI: 10.3892/ijmm_00000264. View

Huang S, Chen I, Liao C, Wang H, Liou S, Hsieh L . Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol. 2008; 45(1):16-22. DOI: 10.1016/j.oraloncology.2008.03.006. View

Chen X, Sturgis E, Lei D, Dahlstrom K, Wei Q, Li G . Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res. 2010; 70(18):7199-208. PMC: 2940953. DOI: 10.1158/0008-5472.CAN-09-4733. View

Michalides R, van Veelen N, Kristel P, Hart A, Loftus B, Hilgers F . Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997; 123(5):497-502. DOI: 10.1001/archotol.1997.01900050045005. View

Clayman G, El-Naggar A, Lippman S, Henderson Y, Frederick M, Merritt J . Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998; 16(6):2221-32. DOI: 10.1200/JCO.1998.16.6.2221. View

Tu H, Chen H, Kao S, Lin S, Liu C, Chang K . MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol. 2008; 87(2):243-52. DOI: 10.1016/j.radonc.2008.03.018. View

Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G . p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003; 3(4):387-402. DOI: 10.1016/s1535-6108(03)00079-5. View

Wan Y, Wu W, Yin Z, Guan P, Zhou B . MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer. 2011; 11:208. PMC: 3115916. DOI: 10.1186/1471-2407-11-208. View

Bischoff J, Kirn D, Williams A, Heise C, Horn S, Muna M . An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996; 274(5286):373-6. DOI: 10.1126/science.274.5286.373. View

10.

Gasco M, Crook T . p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updat. 2004; 6(6):323-8. DOI: 10.1016/j.drup.2003.11.001. View

11.

Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P . Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol. 2005; 207(3):251-9. DOI: 10.1002/path.1838. View

12.

Millon R, Muller D, Schultz I, Salvi R, Ghnassia J, Frebourg T . Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance. Oral Oncol. 2001; 37(8):620-31. DOI: 10.1016/s1368-8375(00)00122-6. View

13.

Sharafinski M, Ferris R, Ferrone S, Grandis J . Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck. 2010; 32(10):1412-21. PMC: 2946515. DOI: 10.1002/hed.21365. View

14.

Shen H, Maki C . Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des. 2011; 17(6):560-8. PMC: 3613239. DOI: 10.2174/138161211795222603. View

15.

Zhuo X, Li Q, Zhou Y, Cai L, Xiang Z, Yuan W . Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. Arch Med Res. 2010; 40(7):625-34. DOI: 10.1016/j.arcmed.2009.09.004. View

16.

Roh J, Kang S, Minn I, Califano J, Sidransky D, Koch W . p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol. 2010; 47(1):8-15. PMC: 3032831. DOI: 10.1016/j.oraloncology.2010.10.011. View

17.

Wang X, Wang J, Jiang X . MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem. 2011; 286(27):23725-34. PMC: 3129153. DOI: 10.1074/jbc.M110.213868. View

18.

Valentin-Vega Y, Barboza J, Chau G, El-Naggar A, Lozano G . High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol. 2007; 38(10):1553-62. PMC: 2699677. DOI: 10.1016/j.humpath.2007.03.005. View

19.

Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N . A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602. DOI: 10.1016/j.cell.2004.11.022. View

20.

Diaz Prado S, Lopez Cedrun J, Luaces Rey R, Villaamil V, Alvarez Garcia A, Valladares Ayerbes M . Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias. Exp Mol Pathol. 2010; 89(2):197-203. DOI: 10.1016/j.yexmp.2010.06.004. View